Larotrectinib discontinuation possible for some paediatric NTRK fusion-positive tumours
Children who respond to larotrectinib therapy for sarcoma with a neurotrophic tyrosine receptor kinase gene fusion may be able to discontinue treatment, indicates research published in the Journal of Clinical Oncology.
Urinary DNA methylation test may improve bladder cancer detection
Measuring levels of urinary DNA methylation may offer a novel and noninvasive test for urothelial cancer, study findings suggest.
OS benefits with perioperative FLOT for resectable oesophageal cancer
Perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin and docetaxel offers better overall survival than preoperative chemoradiotherapy for patients with locally advanced oesopahgeal adenocarcinoma, the ESOPEC trial investigators report.
Adding targeted therapy to TACE improves PFS for unresectable nonmetastatic liver cancer
Progression-free survival findings from two phase 3 clinical trials support the use of targeted therapies in combination with transarterial chemoembolisation for the treatment of patients with unresectable, nonmetastatic hepatocellular carcinoma.
Adjuvant radiation may preserve HRQoL for low-risk breast cancer patients aged 70+
Two-year interim findings from the EUROPA trial indicate that radiotherapy after surgery for low-risk early breast cancer may be better for preserving health-related quality of life for women aged 70 years and older than endocrine therapy.
Primary MMR deficiency ‘underdiagnosed’ among young people with glioma
Primary mismatch repair deficiency in gliomas is underdiagnosed among people younger than 40 years old, say investigators who recommend assessment of the biomarker to help facilitate checkpoint inhibitor therapy.
Polygenic risk score predicts Gleason upgrading during active surveillance
A polygenic risk score may help to identify patients undergoing active surveillance for clinically localised prostate cancer who are at particular risk of an increase in their Gleason grade, US research shows.
Omitting axillary biopsy ‘noninferior’ for early-stage breast cancer survival
For women undergoing breast-conserving surgery for invasive breast cancer, omission of axillary sentinel lymph node biopsy offers noninferior 5-year invasive disease-free survival compared with standard axillary surgery, say the INSEMA trial investigators.
Hypofractionated proton beam therapy regimen feasible for glioblastoma in older patients
A short course of hypofractionated proton beam therapy given alongside temozolomide may offer an improvement in overall survival for patients aged 65 years and older with a new diagnosis of glioblastoma, suggesting findings from a “hypothesis-generating” study.
Routine postoperative imaging may improve pancreatic cancer survival
Research suggests that patients who are invited for routine imaging after pancreatic ductal adenocarcinoma resection have significantly longer overall survival than those who undergo imaging only after the development of symptoms.
